UVIDEM
Navigation Links
UVIDEM in Medical News
IRVINE, Calif., Dec. 31 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ) today announced that as part of the Company's recent
decision to evaluate strategic alternatives, the Company initiated
discussions with sanofi-aventis. Following this, sanofi-aventis has
notified the Company o...
IDM Pharma Reports First Quarter Financial Results
...ollaboration agreement with sanofi-aventis for the uvidem program. As a result of sanofi-aventis' decision to terminate its participation in the uvidem development program in December 2007, no further such revenues related to uvidem were recognized after the first quarter of 2008. ...IDM Pharma Reports First Quarter Financial Results
... a result of sanofi-aventis' decision to terminate its participation in the uvidem development program in December 2007, no further such revenues related to uvidem will be recognized after this quarter. Research and development (R&D) exp...IDM Pharma Reports 2007 Financial Results
...ult of the decision by sanofi-aventis to terminate its participation in the uvidem development program in December 2007. Cash and cash equivalents was $28.4 m...fi-aventis' decision in December 2007 to terminate its participation in the uvidem development program. Interest income increased to $0.4 million for the th...IDM Pharma Reports Third Quarter 2007 Financial Results
...due to an increase in development costs related to uvidem clinical trials, which are reimbursed by sanofi-av...due to an increase in development costs related to uvidem clinical trials, which are reimbursed by sanofi-av...6. The spending related to clinical development of uvidem and clinical development, regulatory filings and m...IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
... IDM Pharma, Inc. today presented preliminary results from a Phase II uvidem (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that uvidem was well tolerated with evidence of efficacy and induction of immune respon...UVIDEM in Medical Technology
...Updates
UVIDEM(R)
The next planned step in the uvidem development program is a Phase 2,
open-label, randomized study of uvidem designed to evaluate patients with
in-transient or...elanoma in the next 60 days.
Patients will receive uvidem or...
...ated results showed that the investigational agent uvidem showed evidence of clinical activity and induction...recognized antigens after vaccination with uvidem were gp100 and MAGE. -- uvidem was well tolerated with only one possibly related ...
...ated results showed that the investigational agent uvidem showed evidence of clinical activity and induction...recognized antigens after vaccination with uvidem were gp100 and MAGE. -- uvidem was well tolerated with only one possibly related ...
IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
...annual meeting in Chicago on June 1-5 2007. uvidem presentation details: -- "Clinical and immu...gned to assess the safety and clinical activity of uvidem in patients with stage III or IV melanoma with mea...atient enrolled in March 2006. About UVIDEM(R) uvidem is a therapeutic specific immunostimulant develope...IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
... - Results show uvidem was well-tolerated with signs of durable disease c...inical trial (DC-MEL-202). The results showed that uvidem was well tolerated with evidence of efficacy and i...arance of anti-TAA specific CD8+ T cells. -- uvidem was well tolerated with toxicity limited to mild e...UVIDEM in Biological Technology
IDM Pharma Reports 2008 Financial Results
...is' decision to terminate its participation in the uvidem development program in December 2007, we will not ... reduction in spending on MEPACT (mifamurtide) and uvidem development, as well as reductions associated with...ecember 2007 to terminate its participation in the uvidem development program. The $3.5 million includes $3......ical experience to IDM Pharma and will lead the regulatory and clinical strategy for L-MTP-PE and the development of the Company's pipeline, including uvidem and IDM-2101. He joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where...
Other TagsAlanineInionFilingFilingFilingOther Contentsligaseligaseligasereactionsreactionsreactionsreactionsreactionsreactionsreactionsreactionsreactionsligationligationligationligationligationligationlimblimblimblimblimblimblimblimblineagelineagelineagelineagedisequilibriumlinkagelinkagelinkagelinkagelinkagelinkerlinkerlinker
AlanineInionOrthoPadStatStripBreatheXSciencewareLabStackFilingHistoPrepIntegreResultNetJResultNetEXXCELCritiView
(Date:11/27/2009)... Voyant Health™ annou...higan) has licensed its TraumaCad Enterprise ortho... workflow solution. , (PR...ounced today that Spectrum Health (Grand Rapids, M...hopedic templating solution and its TraumaCad Exte...
(Date:11/27/2009)... Three new interactive anat...lliams & Wilkins expand health sciences learni... Durham, NC (Vocus) November 27... & Wilkins (LWW), a division of Wolters Kluwer... new anatomy education apps on the App Store. Clem...
(Date:11/26/2009)...In the next 25 years, the number of Americans livi...om 23.7 million in 2009 to 44.1 million in 2034. O...ost triple, rising from $113 billion to $336 billi...sity, researchers based at the University of Chica.... , The number of those with diabetes covered by...
(Date:11/26/2009)...ns get a bigger thrill when on an emotional roller...26 (HealthDay News) -- Call it the fear factor mee...sts that spectators -- especially those who root f...tion if it,s a closely contested match and victory...n despair. , Chew on that this Thanksgiving wee...
(Date:11/26/2009)... Research Triangle Dental (...ral North Carolina, today announced the expansion ...d LUMINEER Dentist, Dr. Doug Macmillan. , ... Triangle Dental is pleased to announce that Dr. D... recently completed an additional advanced trainin...
Breaking Medicine News(10 mins):Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2[0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend[0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store[0] Diabetes cases to double and costs to triple by 2034[0] Watching the Nail-Biting Big Game Hurts So Good[0] Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental
(Date:11/23/2009)...earch presents strong evidence that the "synergist...traffic-related pollution and indoor endotoxin cau...other exposure alone. , Environmental health s...lege of Medicine have shown that children exposed ...nd indoor endotoxin during early life are six time...
(Date:11/23/2009)...er 23, 2009 - The time of day matters to forest tr... produced by a research team led by Professor Malc...vice-principal for research and colleagues in the ...George campus. , Capitalizing on their previou...e research team examined how poplar trees use thei...
(Date:11/23/2009)...urrent research suggests that a common oral bacter...d report by Nichols et al, "Unique Lipids from a C...2 Ligands Capable of Enhancing Autoimmunity," appe...urnal of Pathology . , Multiple sclerosis (MS), ...n and spinal cord, affects nearly 1 in 700 people ...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2Feeling Blue Suicide Prevention Council Partners With the National Institute of Mental Health 52808 1Feeling Blue Suicide Prevention Council Partners With the National Institute of Mental Health 52808 2Iowa Committee Produces Principles for National Efforts to Reform Health Care 52803 1Iowa Committee Produces Principles for National Efforts to Reform Health Care 52803 2Iowa Committee Produces Principles for National Efforts to Reform Health Care 52803 3Texas Kidney Community 3A CMS Authorization to Survey 22 New Dialysis Centers Excellent First Step Toward Opening Additional Pending Facilities Creat 52798 1Texas Kidney Community 3A CMS Authorization to Survey 22 New Dialysis Centers Excellent First Step Toward Opening Additional Pending Facilities Creat 52798 2Texas Kidney Community 3A CMS Authorization to Survey 22 New Dialysis Centers Excellent First Step Toward Opening Additional Pending Facilities Creat 52798 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |